

David P McDonnell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5458697/publications.pdf>

Version: 2024-02-01

43
papers

1,392
citations

430442

18
h-index

329751

37
g-index

43
all docs

43
docs citations

43
times ranked

904
citing authors

#	ARTICLE	IF	CITATIONS
1	Insulin and glucose metabolism with olanzapine and a combination of olanzapine and samidorphan: exploratory phase 1 results in healthy volunteers. <i>Neuropsychopharmacology</i> , 2022, 47, 696-703.	2.8	6
2	Weight Gain and Treatment Interruptions with Second-Generation Oral Antipsychotics: Analysis of Patients with Schizophrenia or Bipolar I Disorder. <i>CNS Spectrums</i> , 2021, 26, 160-160.	0.7	0
3	Qualitative Clinical Trial Exit Interviews Evaluating Treatment Benefit, Burden, and Satisfaction in Patients with Schizophrenia. <i>CNS Spectrums</i> , 2021, 26, 156-157.	0.7	1
4	A Combination of Olanzapine and Samidorphan in Adults with Schizophrenia and Bipolar I Disorder: Overview of Clinical Data. <i>CNS Spectrums</i> , 2021, 26, 170-170.	0.7	1
5	A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: Results from the ENLIGHTEN-2 long-term extension. <i>Schizophrenia Research</i> , 2021, 232, 45-53.	1.1	25
6	An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2021, Volume 17, 2885-2904.	1.0	9
7	Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study. <i>American Journal of Psychiatry</i> , 2020, 177, 1168-1178.	4.0	72
8	Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: results from a 1-year open-label extension study. <i>CNS Spectrums</i> , 2020, 26, 1-10.	0.7	13
9	Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020, 100, 109881.	2.5	9
10	184 Insulin Sensitivity and Glucose Metabolism of Olanzapine and Combination Olanzapine and Samidorphan: A Phase 1 Exploratory Study in Healthy Volunteers. <i>CNS Spectrums</i> , 2020, 25, 316-316.	0.7	2
11	Efficacy and Safety of a Combination of Olanzapine and Samidorphan in Adult Patients With an Acute Exacerbation of Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	1.1	38
12	Olanzapine Plus Samidorphan (ALKS 3831) in Schizophrenia and Comorbid Alcohol Use Disorder. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	1.1	17
13	Bioequivalence of Olanzapine Given in Combination With Samidorphan as a Bilayer Tablet (ALKS 3831) Compared With Olanzapine Alone Tablets: Results From a Randomized, Crossover Relative Bioavailability Study. <i>Clinical Pharmacology in Drug Development</i> , 2019, 8, 459-466.	0.8	19
14	<p>A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 2559-2569.	1.0	42
15	A Phase I Open-Label Study to Evaluate the Effects of Rifampin on the Pharmacokinetics of Olanzapine and Samidorphan Administered in Combination in Healthy Human Subjects. <i>Clinical Drug Investigation</i> , 2019, 39, 477-484.	1.1	14
16	26 A Phase 3 Study to Determine the Antipsychotic Efficacy and Safety of ALKS 3831 in Adult Patients with Acute Exacerbation of Schizophrenia. <i>CNS Spectrums</i> , 2019, 24, 187-188.	0.7	3
17	Effect of Food on the Pharmacokinetics of a Combination of Olanzapine and Samidorphan. <i>Clinical Pharmacology in Drug Development</i> , 2019, 8, 503-510.	0.8	11
18	Olanzapine Plus Samidorphan in Subjects with Schizophrenia and Comorbid Alcohol Use Disorder: Rationale and Design for a Phase II, Double-blind, Randomized Study. <i>Innovations in Clinical Neuroscience</i> , 2019, 16, 15-21.	0.1	4

#	ARTICLE	IF	CITATIONS
19	Pharmacokinetics and Short-term Safety of ALKS 3831, a Fixed-dose Combination of Olanzapine and Samidorphan, in Adult Subjects with Schizophrenia. <i>Clinical Therapeutics</i> , 2018, 40, 1845-1854.e2.	1.1	32
20	Baseline characteristics and hospitalizations in patients with schizophrenia receiving olanzapine long-acting injection: an interim analysis from a non-interventional, prospective observational safety study. <i>BMC Psychiatry</i> , 2015, 15, 278.	1.1	6
21	A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation. <i>Neuropsychiatric Disease and Treatment</i> , 2015, 11, 1349.	1.0	11
22	Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 1125.	1.0	5
23	Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder. <i>International Clinical Psychopharmacology</i> , 2014, 29, 322-331.	0.9	25
24	Within-drug benefit-risk evaluation of olanzapine long-acting injection at one and two years of treatment. <i>International Journal of Methods in Psychiatric Research</i> , 2014, 23, 439-450.	1.1	4
25	A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection. <i>BMC Psychiatry</i> , 2014, 14, 7.	1.1	13
26	Safety and efficacy of olanzapine in the long-term treatment of Japanese patients with bipolar I disorder, depression: An integrated analysis. <i>Psychiatry and Clinical Neurosciences</i> , 2014, 68, 498-505.	1.0	6
27	Incidences of Extrapyramidal Symptoms in Patients with Schizophrenia after Treatment with Long-Acting Injection (Depot) or Oral Formulations of Olanzapine. <i>Clinical Schizophrenia and Related Psychoses</i> , 2014, 7, 216-222.	1.4	7
28	Efficacy and safety of olanzapine for treatment of patients with bipolar depression: Japanese subpopulation analysis of a randomized, double-blind, placebo-controlled study. <i>BMC Psychiatry</i> , 2013, 13, 138.	1.1	20
29	Predictors of psychiatric hospitalization during 6 months of maintenance treatment with olanzapine long-acting injection: post hoc analysis of a randomized, double-blind study. <i>BMC Psychiatry</i> , 2013, 13, 224.	1.1	6
30	Single- and Multiple-Dose Pharmacokinetic, Safety, and Tolerability Profiles of Olanzapine Long-Acting Injection: An Open-Label, Multicenter, Nonrandomized Study in Patients With Schizophrenia. <i>Clinical Therapeutics</i> , 2013, 35, 1890-1908.	1.1	23
31	Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression. <i>British Journal of Psychiatry</i> , 2012, 201, 376-382.	1.7	103
32	Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons. <i>International Journal of General Medicine</i> , 2012, 5, 391.	0.8	10
33	Long-Term Safety and Tolerability of Open-Label Olanzapine Long-Acting Injection in the Treatment of Schizophrenia: 190-Week Interim Results. <i>Clinical Medicine Insights Psychiatry</i> , 2011, 3, CMPsy.S6659.	0.4	12
34	Dose correspondence between olanzapine long-acting injection and oral olanzapine. <i>International Clinical Psychopharmacology</i> , 2011, 26, 35-42.	0.9	178
35	Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia. <i>BMC Psychiatry</i> , 2011, 11, 152.	1.1	15
36	Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia. <i>BMC Psychiatry</i> , 2011, 11, 28.	1.1	21

#	ARTICLE	IF	CITATIONS
37	Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapine. <i>Human Psychopharmacology</i> , 2011, 26, 422-433.	0.7	21
38	Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases. <i>BMC Psychiatry</i> , 2010, 10, 43.	1.1	99
39	Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism. <i>BMC Psychiatry</i> , 2010, 10, 45.	1.1	76
40	Olanzapine Long-Acting Injection: A 24-Week, Randomized, Double-Blind Trial of Maintenance Treatment in Patients With Schizophrenia. <i>American Journal of Psychiatry</i> , 2010, 167, 181-189.	4.0	181
41	Classifying Patients by Antipsychotic Adherence Patterns Using Latent Class Analysis: Characteristics of Nonadherent Groups in the California Medicaid (Medi-Cal) Program. <i>Value in Health</i> , 2008, 11, 48-56.	0.1	61
42	D2 Receptor Occupancy of Olanzapine Pamoate Depot Using Positron Emission Tomography: An Open-label Study in Patients with Schizophrenia. <i>Neuropsychopharmacology</i> , 2008, 33, 298-304.	2.8	65
43	An 8-Week, Double-Blind, Randomized, Placebo-Controlled Study of Olanzapine Long-Acting Injection in Acutely Ill Patients With Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 790-799.	1.1	106